Evidence map›Paper›PMID 12239290›Full record

ArticleJournal of virology2002

Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C.

V Novitsky, H Cao, N Rybak, P Gilbert, M F McLane, S Gaolekwe, T Peter, I Thior, T Ndung'u, R Marlink and 2 more

2 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 54 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02042248 phase1completednot on this mapstarted 2014, after this paper: background citation

IGHID 1309 -A Phase I Study to Evaluate the Kinetics of the Immunologic Response and Virologic Impact of AGS-004 in HIV-Infected Individuals Suppressed on Antiretroviral Therapy Initiated During Acute and Chronic HIV Infection

TypeinterventionalSponsorCynthia L Gay, MDRan2014 to 2016Enrolled6ConditionsHIVArmsAGS-004
NCT02707900 phase1terminatednot on this mapstarted 2016, after this paper: background citation

IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)

TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2016 to 2018Enrolled6ConditionsHIV-1 InfectionArmsVorinostat, AGS-004
3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 1 synthesis or guideline pooled it, 112 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Genome-wide association study reveals genetic variants associated with HIV-1C infection in a Botswana study population.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

V NovitskyDepartment of Immunology and Infectious Diseases, Harvard School of Public Health, FXB-402, 651 Huntington Avenue, Boston, MA 02115, USA.
H Cao
N Rybak
P Gilbert
M F McLane
S Gaolekwe
T Peter
I Thior
T Ndung'u
R Marlink
T H Lee
M Essex
Harvard University · USBotswana Harvard AIDS Institute Partnership · BWHarvard University Press · USUniversity of Washington · US

Funding

INTERNATIONAL TRAINING IN AIDS-RELATED EPIDEMIOLOGYD43TW000004 · FIC · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ESSEX, MYRON E · 1988 to 2012
$13.4M
PREVENTION OF MILK-BORNE TRANSMISSION OF HIV IN BOTSWANAR01HD037793 · NICHD · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ESSEX, MYRON E · 2000 to 2004
$6.9M
IDENTIFICATION OF HLA RESTRICTED CTL EPITOPES OF HIV-1 CR01AI047067 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ESSEX, MYRON E · 2000 to 2004
$2.5M
GENOMIC ANALYSIS OF HIV-1 TRANSMISSION IN BOTSWANAR01AI043255 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ESSEX, MYRON E · 1999 to 2003
$2.2M
FIC NIH HHS D43 TW000004FIC NIH HHS TW 00004NIAID NIH HHS AI 43255NIAID NIH HHS AI 47067NIAID NIH HHS R01 AI043255NIAID NIH HHS R01 AI047067NICHD NIH HHS HD 37793NICHD NIH HHS R01 HD037793
6 · The paper itself

Abstract

A systematic analysis of immune responses on a population level is critical for a human immunodeficiency virus type 1 (HIV-1) vaccine design. Our studies in Botswana on (i) molecular analysis of the HIV-1 subtype C (HIV-1C) epidemic, (ii) frequencies of major histocompatibility complex class I HLA types, and (iii) cytotoxic T-lymphocyte (CTL) responses in the course of natural infection allowed us to address HIV-1C-specific immune responses on a population level. We analyzed the magnitude and frequency of the gamma interferon ELISPOT-based CTL responses and translated them into normalized cumulative CTL responses. The introduction of population-based cumulative CTL responses reflected both (i) essentials of the predominant virus circulating locally in Botswana and (ii) specificities of the genetic background of the Botswana population, and it allowed the identification of immunodominant regions across the entire HIV-1C. The most robust and vigorous immune responses were found within the HIV-1C proteins Gag p24, Vpr, Tat, and Nef. In addition, moderately strong responses were scattered across Gag p24, Pol reverse transcriptase and integrase, Vif, Tat, Env gp120 and gp41, and Nef. Assuming that at least some of the immune responses are protective, these identified immunodominant regions could be utilized in designing an HIV vaccine candidate for the population of southern Africa. Targeting multiple immunodominant regions should improve the overall vaccine immunogenicity in the local population and minimize viral escape from immune recognition. Furthermore, the analysis of HIV-1C-specific immune responses on a population level represents a comprehensive systematic approach in HIV vaccine design and should be considered for other HIV-1 subtypes and/or different geographic areas.

Indexed as

Amino Acid SequenceEpitope MappingEpitopes, T-LymphocyteHIV-1HIV AntigensHIV InfectionsHumansImmunodominant EpitopesMolecular Sequence DataT-Lymphocytes, CytotoxicEpitopes, T-LymphocyteHIV AntigensImmunodominant Epitopes

Identifiers

PMID12239290
PMCPMC136554
OpenAlexW2102159102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.